Updated Feb 18, 2020 - Health

Coronavirus vaccines in development aren't a short-term cure

Coronavirus under a microscope. Photo: BSIP/UIG Via Getty Images

There are a dozen research projects underway to try to come up with a vaccine for the Chinese coronavirus, Biocentury reports.

What's new: Drug maker Sanofi Pasteur is entering the race to develop a vaccine by partnering with the U.S. Biomedical Advanced Research and Development Authority — known as BARDA, the Department of Homeland Security announced Tuesday.

Yes, but: "A vaccine is not a short-term solution controlling this epidemic, but it is an important tool that could control it for subsequent years if this virus continues to circulate in humans," said Andy Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health.

Where it stands: Chinese researchers cracked the virus' genetic sequence and shared it with other scientists.

Go deeper: How the world is responding to the coronavirus outbreak

Go deeper

Podcast: The race for a coronavirus vaccine

On Monday, a woman in Seattle became America’s first human subject of a novel coronavirus vaccine trial. Dan and Axios' Bob Herman dig into the vaccine development process and why a young biotech company is leading the pack.

Go deeper: Inside vaccine-maker Moderna Therapeutics

U.S. volunteer receives first shot of experimental coronavirus vaccine

Moderna has developed the first experimental coronavirus vaccine, but an approved treatment is more than a year away. Photo: David L. Ryan/The Boston Globe via Getty Images

A healthy U.S. volunteer received the first dose of an experimental coronavirus vaccine, a potential defense against the virus if it becomes a long-term threat.

Where it stands: The trial will ultimately give 45 volunteers two doses about 28 days apart in order to test the vaccine's effectiveness in protecting the subjects against COVID-19. If successful, several more trials with larger subject groups will be needed to prove whether there are common side effects.

Go deeperArrowMar 16, 2020 - Health

We're still in the early days of coronavirus vaccine research

Illustration: Sarah Grillo/Axios

Moderna has moved incredibly quickly to begin testing a potential vaccine for the new coronavirus in U.S. patients. The biotech company went from taking the genetic sequence of the new coronavirus to manufacturing its first batch of vials in less than a month.

Reality check: Best-case scenario, a vaccine could be ready for production by next year — but that's assuming the drug proves to be both safe and effective, which is completely unknown right now.

Go deeperArrowMar 18, 2020 - Health